Ben Chang

Mr. Chang is Chairman and Chief Executive Officer of PhorMed, where he leads the company’s strategic growth initiatives, oversees the advancement of its clinical development programs, and directs the continued expansion of its pipeline. He has been the driving force behind PhorMed’s patient-focused drug development model, which utilizes patient insights to inform clinical research programs focused on next-generation, innovative treatment to help people living with rare oncological diseases. Mr. Chang brings more than 30 years of executive and pharmaceutical industry experience. His background spans international banking, venture capital, mergers and acquisitions, finance, public-market transactions, and operational management. He is also a co-author of 2 patents. Prior to PhorMed, Ben held leadership roles at Rich Pharmaceuticals and Biosuccess Biotech.